Compare VCEL & LC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VCEL | LC |
|---|---|---|
| Founded | 1989 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1996 | 2008 |
| Metric | VCEL | LC |
|---|---|---|
| Price | $33.54 | $14.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $58.50 | $22.67 |
| AVG Volume (30 Days) | 423.1K | ★ 1.8M |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.00 | ★ 157.78 |
| EPS | 0.32 | ★ 1.16 |
| Revenue | $276,259,000.00 | ★ $314,702,000.00 |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $17.96 | $15.91 |
| P/E Ratio | $105.00 | ★ $12.66 |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $29.24 | $7.90 |
| 52 Week High | $49.10 | $21.67 |
| Indicator | VCEL | LC |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 37.83 |
| Support Level | $29.59 | $12.25 |
| Resistance Level | $38.48 | $17.41 |
| Average True Range (ATR) | 1.47 | 0.83 |
| MACD | -0.36 | -0.01 |
| Stochastic Oscillator | 9.47 | 7.53 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.